Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2025 16:05 ET | Source: Surrozen, Inc.

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Surrozen Reports First Quarter 2025 Financial Results and Business Update
May 08, 2024 16:05 ET | Source: Surrozen, Inc.

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Provides First Quarter 2024 Financial Results and Business Update
April 03, 2024 08:40 ET | Source: Surrozen, Inc.

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
April 01, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
November 08, 2023 16:05 ET | Source: Surrozen, Inc.

Surrozen Provides Third Quarter 2023 Financial Results

Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical...
August 09, 2023 16:05 ET | Source: Surrozen, Inc.

Surrozen Provides Second Quarter 2023 Financial Results

SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in...
June 01, 2020 11:00 ET | Source: Samumed, LLC.

Michael White, Ph.D. joins Samumed as Chief Scientific Officer

SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, a clinical-stage biotechnology company pioneering Wnt Pathway therapeutics for major diseases, announced today that Dr. Michael White will...
May 22, 2020 09:00 ET | Source: Samumed, LLC.

Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis

SAN DIEGO, May 22, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates...